BR112022023261A2 - Imunização bacteriana usando vacina de nanopartícula - Google Patents

Imunização bacteriana usando vacina de nanopartícula

Info

Publication number
BR112022023261A2
BR112022023261A2 BR112022023261A BR112022023261A BR112022023261A2 BR 112022023261 A2 BR112022023261 A2 BR 112022023261A2 BR 112022023261 A BR112022023261 A BR 112022023261A BR 112022023261 A BR112022023261 A BR 112022023261A BR 112022023261 A2 BR112022023261 A2 BR 112022023261A2
Authority
BR
Brazil
Prior art keywords
bacterial
nanoparticle vaccine
immunization
bacterial immunization
methods
Prior art date
Application number
BR112022023261A
Other languages
English (en)
Inventor
Adamo Roberto
Carboni Filippo
Cozzi Roberta
Margarit Y Ros Immaculada
Rosaria Romano Maria
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of BR112022023261A2 publication Critical patent/BR112022023261A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

IMUNIZAÇÃO BACTERIANA USANDO VACINA DE NANOPARTÍCULA. A presente invenção refere-se a métodos de indução de uma resposta imunogênica contra um polissacarídeo ou oligossacarídeo bacteriano e construtos e composições para uso em tais métodos.
BR112022023261A 2020-06-12 2021-06-11 Imunização bacteriana usando vacina de nanopartícula BR112022023261A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063038277P 2020-06-12 2020-06-12
PCT/IB2021/055159 WO2021250628A1 (en) 2020-06-12 2021-06-11 Bacterial immunization using nanoparticle vaccine

Publications (1)

Publication Number Publication Date
BR112022023261A2 true BR112022023261A2 (pt) 2022-12-27

Family

ID=76502770

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022023261A BR112022023261A2 (pt) 2020-06-12 2021-06-11 Imunização bacteriana usando vacina de nanopartícula

Country Status (8)

Country Link
US (1) US20230210975A1 (pt)
EP (1) EP4164681A1 (pt)
JP (1) JP2023529925A (pt)
CN (1) CN115803050A (pt)
BR (1) BR112022023261A2 (pt)
CA (1) CA3185429A1 (pt)
MX (1) MX2022015860A (pt)
WO (1) WO2021250628A1 (pt)

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3071552D1 (en) 1979-09-21 1986-05-22 Hitachi Ltd Semiconductor switch
US4356170A (en) 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4695624A (en) 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
IT1187753B (it) 1985-07-05 1987-12-23 Sclavo Spa Coniugati glicoproteici ad attivita' immunogenica trivalente
US5374426A (en) 1986-09-03 1994-12-20 University Of Saskatchewan Rotavirus nucleocapsid protein VP6 in vaccine compositions
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
EP0563091A1 (en) 1990-12-20 1993-10-06 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccines based on hepatitis b surface antigen
EP0911036A3 (en) 1992-02-11 2001-05-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Dual carrier immunogenic construct
CA2171942C (en) 1993-09-22 2010-12-14 Andrew Lees Method of activating soluble carbohydrate using novel cyanylating reagents for the production of immunogenic constructs
NZ304715A (en) 1995-03-22 1999-07-29 Jackson H M Found Military Med Production of immunogenic constructs using organic cyanylating reagents to activate carbohydrates and then coupling the carbohydrate to a protein, peptide or hapten
WO1996030523A2 (en) 1995-03-31 1996-10-03 Hans Wolf Antigen presentation system based on retrovirus-like particles
US6284884B1 (en) 1995-06-07 2001-09-04 North American Vaccine, Inc. Antigenic group B streptococcus type II and type III polysaccharide fragments having a 2,5-anhydro-D-mannose terminal structure and conjugate vaccine thereof
GB9621091D0 (en) 1996-10-09 1996-11-27 Fondation Pour Le Perfectionem Attenuated microorganisms strains and their uses
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
US6146902A (en) 1998-12-29 2000-11-14 Aventis Pasteur, Inc. Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions
US7320793B2 (en) 2001-01-19 2008-01-22 Cytos Biotechnology Ag Molecular antigen array
AU2002339224B2 (en) 2001-09-14 2008-10-09 Kuros Us Llc Packaging of immunostimulatory substances into virus-like particles: method of preparation and use
JP4360906B2 (ja) 2001-09-14 2009-11-11 サイトス バイオテクノロジー アーゲー ウィルス様粒子によって誘導される免疫応答を高めるための、抗原提示細胞のインビボでの活性化
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
EP1736538A1 (en) 2005-06-21 2006-12-27 Cytos Biotechnology AG Process for the preparative purification of virus-like-particles (VLPs)
EP2575868A1 (en) * 2010-06-07 2013-04-10 Pfizer Vaccines LLC Ige ch3 peptide vaccine
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
US9855325B2 (en) 2012-10-03 2018-01-02 Glaxosmithkline Biologicals Sa Immunogenic composition
AU2016258284C1 (en) 2015-05-04 2020-09-03 Pfizer Inc. Group B Streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
KR20210011083A (ko) * 2015-09-10 2021-01-29 인벤트프라이즈 엘엘씨 다가 vlp 접합체
US10961283B2 (en) 2016-06-27 2021-03-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Self-assembling insect ferritin nanoparticles for display of co-assembled trimeric antigens
US20200254083A1 (en) 2017-06-16 2020-08-13 Glaxosmithkline Biologicals Sa Method of treatment
EP3650044A1 (en) * 2018-11-06 2020-05-13 ETH Zürich Anti-glycan vaccines

Also Published As

Publication number Publication date
EP4164681A1 (en) 2023-04-19
WO2021250628A1 (en) 2021-12-16
CA3185429A1 (en) 2021-12-16
CN115803050A (zh) 2023-03-14
MX2022015860A (es) 2023-01-24
US20230210975A1 (en) 2023-07-06
JP2023529925A (ja) 2023-07-12

Similar Documents

Publication Publication Date Title
BRPI1013780B8 (pt) Composição imunogênica útil para imunização contra staphylococcus aureus, seu método de preparação e composição farmacêutica
EP3616716A3 (en) Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
EA201691478A1 (ru) Новый полисахарид и его применения
BR112013006396A2 (pt) composições imunogênicas
BR112017013891A2 (pt) composições imunogênicas para uso em vacinas pneumocócicas
BR112018007812A2 (pt) polissacarídeo capsular, processo para preparar um polissacarídeo capsular e para fabricar uma vacina, composição imunogênica, vacina, métodos para tratamento ou prevenção de uma infecção, para imunizar um hospedeiro humano e para induzir uma resposta imune, e, uso de uma composição imunogênica.
MX2019008564A (es) Composiciones inmunogenicas para su uso en vacunas neumococicas.
BRPI0607374A2 (pt) vacinas de vesìculas baseadas em gna1870 para proteção de amplo espectro contra doenças causadas por neisseria meningitidis
BR112014018815A8 (pt) Composição imunogênica compreendendo conjugado proteína-polissacarídeo x de n. meningitidis
NZ591103A (en) Methods and compositions relating to synthetic beta-1,6 glucosamine oligosaccharides
BR112014032636A2 (pt) Vacinas atenuadas de streptococcus suis e métodos de produção e usos das mesmas
BR112012028893A2 (pt) composições imunoestimuladoras e de vacina
BRPI0918806A2 (pt) composição compreendendo quitosana para administração ocular de vaninas em aves
WO2017214596A8 (en) Compositions and methods for preventing and treating zika virus infection
CO2021001926A2 (es) Composiciones de escherichia coli y métodos de estas
BR112019007803A2 (pt) formulações de vacina de glicoconjugado contra expec
PH12021550479A1 (en) Dengue vaccine unit dose and administration thereof
WO2017156511A8 (en) Live attenuated zika virus vaccine
BRPI0519381A2 (pt) bactÉria atenuada viva de pasteurella multocida, vacina atenuada viva para a proteÇço de animais ou humanos contra infecÇço por pasteurella multocida ou seu efeitos patogÊnicos, uso de uma bactÉria atenuada viva, mÉtodo para a preparaÇço de uma vacina, e, teste diagnàstico para a detecÇço de dna ou rna associado com pasteurella multocida
BR112015022582A2 (pt) molécula de ácido nucleico, plasmídeo, vacina, e, uso de um plasmídeo
BR112022016507A2 (pt) Vacinas contra o coronavírus e métodos de uso
BR112019004303A2 (pt) composição de conjugados multivalentes de polissacarídeo capsular pneumocócico-proteína portadora e uso da mesma
MX2021007502A (es) Formulaciones y métodos de vacuna de norovirus.
BR112018074910A2 (pt) composição imunológica, e, método de indução de uma resposta imunológica contra o vírus da influenza equina em um sujeito
BR112022023261A2 (pt) Imunização bacteriana usando vacina de nanopartícula